a public good project by the
Synthesis
Company
of California

© 2026

Michael A. Letavic | doi.page

0 works0 citations0 h-index

Michael A. Letavic

Janssen (Belgium)(BE)Janssen (United States)(US)

Publications by Year

Research Areas

Adenosine and Purinergic Signaling, Mast cells and histamine, Chemical Synthesis and Analysis, Phenothiazines and Benzothiazines Synthesis and Activities, Asymmetric Synthesis and Catalysis

Most-Cited Works

→ Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567(2013)193 cited
→ Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy(2016)162 cited
→ Histamine H3 receptor antagonists: From target identification to drug leads(2006)134 cited
→ microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus(2015)109 cited
→ Enantioselective Total Synthesis of Gracilins B and C Using Catalytic Asymmetric Diels-Alder Methodology(1995)99 cited
→ Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models(2016)92 cited

→ Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates(2016)

88 cited

→ Asymmetric induction in reactions of styrenes with 1,4-benzoquinones utilizing chiral titanium(IV) complexes(1991)87 cited

→ Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia(2015)81 cited

→ Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia(2018)79 cited